Clinical trial · Observational
VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
A Robust Biomarker of Aggressive HCC and the Response for Adjuvant PD-1 Inhibitors or Combined TKIs Following Liver Resection: Vessels That Encapsulate Tumor Clusters
NCT06253364CI-TRIAL-00074992completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 monoclonal antibody and lenvatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Liver resection group
- description
- No adjuvant therapy after hepatectomy.
- label
- Adjuvant PD-1 group
- description
- Adjuvant therapy with PD-1 monoclonal antibody after hepatectomy
- interventionNames
- Drug: PD-1 monoclonal antibody and lenvatinib
- label
- Adjuvant PD-1 plus Lenvatinib group
- description
- Adjuvant therapy with PD-1 monoclonal antibody combined with lenvatinib after hepatectomy.
- interventionNames
- Drug: PD-1 monoclonal antibody and lenvatinib
Primary outcomes (1)
- measure
- Disease -free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Underwent radical hepatectomy * No preoperative treatment * Pathological confirmed HCC * High-risk recurrent HCC * Not receiving any adjuvant therapy or receiving adjuvant therapy with PD-1 monotherapy or receiving adjuvant therapy with PD-1 monotherapy in combination with Lenvatinib after surgery Exclusion Criteria: * Macrovascular invasion * No available wax blocks * No complete clinical information
References
Publications (0)
Data not yet available
No reference posted for this study.